Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 2005
Issue release date: May 2005
Neuroimmunomodulation 2005;12:131–140

IL-6 and Its Circadian Secretion in Humans

Vgontzas A.N. · Bixler E.O. · Lin H.-M. · Prolo P. · Trakada G. · Chrousos G.P.
aSleep Research and Treatment Center, Department of Psychiatry and bHealth Evaluation Sciences, Penn State College of Medicine, Hershey, Pa., cDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Calif., and dPediatric and Reproductive Endocrinology Branch, National Institutes of Health, Bethesda, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Interleukin-6 (IL-6) is a pleiotropic cytokine produced by numerous types of immune and nonimmune cells and is involved in many pathophysiologic mechanisms in humans. Many studies suggest that IL-6 is a putative ‘sleep factor’ and its circadian secretion correlates with sleep/sleepiness. IL-6 is elevated in disorders of excessive daytime sleepiness such as narcolepsy and obstructive sleep apnea. It correlates positively with body mass index and may be a mediator of sleepiness in obesity. Also the secretion of this cytokine is stimulated by total acute or partial short-term sleep loss reflecting the increased sleepiness experienced by sleep-deprived individuals. Studies that evaluated the 24-hour secretory pattern of IL-6 in healthy young adults suggest that IL-6 is secreted in a biphasic circadian pattern with two nadirs at about 08.00 and 21.00, and two zeniths at about 19.00 and 05.00 h. In contrast, following sleep deprivation or in disorders of sleep disturbance, e.g., insomnia, IL-6 peaks during the day and, based on the level of stress system activity, i.e., cortisol secretion, contributes to either sleepiness and deep sleep (low cortisol) or feelings of tiredness and fatigue and poor sleep (high cortisol). In order to address concerns about the potential impact of differences of IL-6 levels between the beginning and the end of the 24-hour blood-drawing experiment, we proceeded with a cosinor analysis of ‘detrended’ data in young and old healthy individuals. This new analysis did not affect the biphasic circadian pattern of IL-6 secretion in young adults, while it augmented the flattened circadian pattern in old individuals in whom the difference was greater. Finally, IL-6 appears to be somnogenic in rats and exhibits a diurnal rhythm that follows the sleep/wake cycle in these animals. We conclude that IL-6 is a mediator of sleepiness and its circadian pattern reflects the homeostatic drive for sleep.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Opp MR: Cytokines and sleep: The first hundred years. Brain Behav Immun 2004;18:295–297.
  2. Opp MR, Kapas L, Toth LA: Cytokine involvement in the regulation of sleep. Proc Soc Exp Biol Med 1992;201:16–27.
  3. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM: The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med 1986;4:309–318.

    External Resources

  4. Kapas L, Hong L, Cady AB, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM: Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-α and TNFα fragments. Am J Physiol 1992;263:708–715.
  5. Reincke M, Heppner C, Petzke F, Allolio B, Arlt W, Mbulamberi D, Siekmann L, Vollmer D, Winkelmann W, Chrousos GP: Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosomiasis. Neuroimmunomodulation 1994;1:14–22.
  6. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690–1694.
  7. Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP: Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 1996;81:2303–2306.
  8. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP: Elevation of cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313–1316.
  9. Haack M, Kraus T, Schuld A, Dalal M, Koethe D, Pollmächer T: Dirunal variations of interleukin-6 plasma levels are confounded by blood drawing procedures. Psychoneuroendocrinology 2002;27:921–931.
  10. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–137.
  11. Papanicolaou DA, Vgontzas AN: Interleukin-6: The endocrine cytokine. J Clin Endocrinol Metab 2000;85:1331–1333.
  12. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.
  13. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP: The differential effect of food intake and β-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999;84:2126–2133.
  14. Breuninger LM, Dempsey WL, Uhl J, Murasko DM: Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol 1993;69:205–214.
  15. Girasole G, Jilka RI, Passeri DC, Boswell S, Boder G, Williams DC, Manolagas SC: 17 β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanisms for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883–891.
  16. van Good J, van Vugt H, Helle M, Aarden LA: The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol 1990;57:200–210.
  17. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, Gold PW, Deuster PA, Chrousos GP: Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996;271:E601–E605.
  18. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305–311.
  19. Torpy DJ, Tsigos C, Lotsikas AJ, Defensor R, Chrousos GP, Papanicolaou DA: Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism 1998;47:1289–1293.
  20. Boelen A, Maas MA, Lowik CW, Platvoet MC, Wiersinga WM: Induced illness in interleukin-6 (IL-6) knock-out mice: A causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinology 1996;137:5250–5254.
  21. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP: Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995;268:E813–E819.
  22. Vgontzas AN, Chrousos GP: Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002;31:15–36.
  23. Hinze-Selch D, Wetter TC, Zhang Y, Lu HC, Albert AD, Mullington J: In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998;50:1149–1152.
  24. Okun ML, Giese S, Lin L, Einen M, Mignot E, Coussons-Read ME: Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun 2004;18:326–332.
  25. Vgontzas AN, Bixler EO, Tan TL, Kantner D, Martin LF, Kales A: Obesity without sleep apnea is associated with daytime sleepiness. Arch Intern Med 1998;158:1333–1337.
  26. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP: Sleep apnea and daytime sleepiness and fatigue: Relations with visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–1158.
  27. Vgontzas AN, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, Prolo P, Wong ML, Licinio J, Gold PW, Hermida RC, Mastorakos G, Chrousos GP: Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603–2607.
  28. Shearer WT, Reuben JM, Mullington JM, Price NJ, Lee BN, Smith EO, Szuba MP, Van Dongen HP, Dinges DF: Soluble TNF-α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001;107:165–170.
  29. Vgontzas AN, Zoumakis M, Bixler EO, Lin H-M, Follett H, Chrousos GP: Effects of one week of modest sleep restriction to 6 hours per night on daytime sleepiness, performance, IL-6, TNF, and cortisol plasma levels. J Clin Endocrinol Metab 2004;89:2119–2126.
  30. Vgontzas AN, Zoumakis DA, Papanicolaou EO, Bixler EO, Prolo P, Lin HM, Vela-Bueno A, Kales A, Chrousos GP: Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887–892.
  31. Vgontzas AN, Zoumakis M, Bixler EO, Lin HM, Prolo P, Vela-Bueno A, Kales A, Chrousos GP: Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: Physiologic and therapeutic implications. J Clin Endocrinol Metab 2003;88:2087–2095.
  32. Vgontzas AN, Mastorakos G, Bixler EO, Kales A, Gold PW, Chrousos GP: Sleep deprivation effects on the activity of the hypothalamic-pituitary-adrenal and growth axes: Potential clinical implications. Clin Endocrinol 1999;51:205–215.
  33. Vgontzas AN, Bixler EO, Lin H-M, P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP: Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab 2001;86:3787–3794.
  34. Späth-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, Born J: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573–1579.
  35. Mullington JC, Korth D, Hermann A, Orth A, Galanos C, Holsboer F, Pollmacher T: Dose-dependent effects of endotoxin on human sleep. Am J Physiol 2000;278:R947–R955.
  36. Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F: Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992;242:53–56.
  37. Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, Lis S, Postler E, Voderholzer U, Berger M: Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Invest 1994;72:315.
  38. Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodell MM, Weatherbee JA, Young MR, Nenchausky BM, Scheving LE: Circadian characteristics of circulating interleukin-6 in men. J Allergy Clin Immunol 1995;95:1029–1035.
  39. Redwine L, Hauger RL, Gillin JC: Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 2000;85:3597–3603.
  40. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmächer T: Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000;12:694–698.
  41. Seiler W, Müller H, Hiemke C: Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. Clin Chem 1994;40:1778–1779.
  42. Gudmundsson A, Ershler WB, Goodman B, Lent SJ, Barczi S, Carnes M: Serum concentrations of interleukin-6 are increased when sampled through an indwelling venous catheter. Clin Chem 1997;43:2199–2201.
  43. Opp MR, Cady AB, Johannsen L, Krueger JM: Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav 1989;45:1069–1072.
  44. Hogan D, Morrow JD, Smith EM, Opp MR: Interleukin-6 alters sleep of rats. J Neuroimmunol 2003;137:59–66.
  45. Guan Z, Vgontzas AN, Omori T, Peng X, Bixler EO, Fang J: Interleukin-6 levels fluctuate with the light-dark cycle in the brain and peripheral tissue in rats. Brain Behav Immun, in press.
  46. Šereš J, Herichova I, Roman O, Bornstein S, Jurčovičová J: Evidence for daily rhythms of the expression of proopiomelanocortin, interleukin-1-beta and interleukin-6 in adenopituitaries of male Long-Evans rats: Effect of adjuvant arthritis. Neuroimmunomodulation 2004;11:316–322.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50